Baxter International Inc (NYSE:BAX) SVP Scott Pleau Sells 9,710 Shares

Baxter International Inc (NYSE:BAX) SVP Scott Pleau sold 9,710 shares of the firm’s stock in a transaction that occurred on Friday, March 29th. The shares were sold at an average price of $80.00, for a total transaction of $776,800.00. Following the sale, the senior vice president now directly owns 29,786 shares of the company’s stock, valued at approximately $2,382,880. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Baxter International stock traded down $0.07 on Friday, hitting $76.18. 2,367,880 shares of the company’s stock were exchanged, compared to its average volume of 3,149,286. The stock has a market capitalization of $38.91 billion, a PE ratio of 24.98, a P/E/G ratio of 1.84 and a beta of 1.02. Baxter International Inc has a 1 year low of $61.05 and a 1 year high of $82.25. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.09 and a quick ratio of 1.50.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, April 25th. The medical instruments supplier reported $0.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.08. The business had revenue of $2.63 billion for the quarter, compared to analysts’ expectations of $2.61 billion. Baxter International had a net margin of 14.60% and a return on equity of 19.10%. The company’s revenue was down 1.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.70 EPS. As a group, research analysts anticipate that Baxter International Inc will post 3.27 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Friday, March 1st were paid a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 1.00%. The ex-dividend date was Thursday, February 28th. Baxter International’s dividend payout ratio is presently 24.92%.

Several institutional investors have recently modified their holdings of the company. Martingale Asset Management L P boosted its position in Baxter International by 1.6% during the third quarter. Martingale Asset Management L P now owns 722,269 shares of the medical instruments supplier’s stock valued at $55,681,000 after purchasing an additional 11,546 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Baxter International by 0.9% during the third quarter. Dimensional Fund Advisors LP now owns 1,188,146 shares of the medical instruments supplier’s stock valued at $91,588,000 after purchasing an additional 10,917 shares during the last quarter. Brown Advisory Inc. boosted its position in Baxter International by 7.1% during the third quarter. Brown Advisory Inc. now owns 96,165 shares of the medical instruments supplier’s stock valued at $7,413,000 after purchasing an additional 6,375 shares during the last quarter. Baird Financial Group Inc. boosted its position in Baxter International by 8.9% during the third quarter. Baird Financial Group Inc. now owns 103,467 shares of the medical instruments supplier’s stock valued at $8,048,000 after purchasing an additional 8,458 shares during the last quarter. Finally, Standard Life Aberdeen plc boosted its position in Baxter International by 121.2% during the third quarter. Standard Life Aberdeen plc now owns 5,743,738 shares of the medical instruments supplier’s stock valued at $442,813,000 after purchasing an additional 3,146,868 shares during the last quarter. Institutional investors and hedge funds own 86.44% of the company’s stock.

Several brokerages recently weighed in on BAX. Wells Fargo & Co raised their price target on shares of Baxter International from $80.00 to $89.00 and gave the company an “outperform” rating in a research report on Wednesday, April 3rd. Zacks Investment Research downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, April 2nd. Barclays lifted their target price on shares of Baxter International from $72.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Monday, April 15th. Cowen set a $75.00 target price on shares of Baxter International and gave the stock a “hold” rating in a research report on Monday. Finally, Morgan Stanley lifted their target price on shares of Baxter International from $80.00 to $83.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 5th. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $78.12.

TRADEMARK VIOLATION NOTICE: This article was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/04/27/scott-pleau-sells-9710-shares-of-baxter-international-inc-bax-stock.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

See Also: What are convertible shares? 

Insider Buying and Selling by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.